François Ghiringhelli INSERM U866, France
2 protocols

Valentin Derangère INSERM U866, France
2 protocols

Mélanie Bruchard INSERM U866, France
2 protocols

Frédérique Végran
  • INSERM U866, France
Research focus
  • Immunology
  • 2 Author merit


Ph.D. in Cellular and Molecular Biology, Dijon, France, 2007

Current position

Molecular Biologist in Centre GF Leclerc, Dijon, France

Publications (since 2013)

  1. Thibaudin, M., Chaix, M., Boidot, R., Végran, F., Derangère, V., Limagne, E., Berger, H., Ladoire, S., Apetoh, L. and Ghiringhelli, F. (2016). Human ectonucleotidase-expressing CD25 Th17 cells accumulate in breast cancer tumors and exert immunosuppressive functions. Oncoimmunology 5(1): e1055444.
  2. Bruchard, M., Boidot, R., Ghiringhelli, F. and Végran, F. (2015). Transcriptome analysis of TH2 CD4(+) T cells differentiated from wild-type and NLRP3KO mice. Genom Data 5: 314-315.
  3. Bruchard, M., Rebé, C., Derangère, V., Togbé, D., Ryffel, B., Boidot, R., Humblin, E., Hamman, A., Chalmin, F., Berger, H., Chevriaux, A., Limagne, E., Apetoh, L., Vegran, F. and Ghiringhelli, F. (2015). The receptor NLRP3 is a transcriptional regulator of TH2 differentiation. Nat Immunol 16(8): 859-870.
  4. Schmitt, E., Végran, F., Chevrier, S., Burillier, L., Cadouot, M., Lizard-Nacol, S., Coudert, B., Fumoleau, P., Arnould, L. and Boidot, R. (2015). Transcriptional expression of 8 genes predicts pathological response to first-line docetaxel + trastuzumab-based neoadjuvant chemotherapy. BMC Cancer 15: 169.
  5. Végran, F., Apetoh, L. and Ghiringhelli, F. (2015). Th9 cells: a novel CD4 T-cell subset in the immune war against cancer. Cancer Res 75(3): 475-479.
  6. Derangère, V., Chevriaux, A., Courtaut, F., Bruchard, M., Berger, H., Chalmin, F., Causse, S. Z., Limagne, E., Végran, F., Ladoire, S., Simon, B., Boireau, W., Hichami, A., Apetoh, L., Mignot, G., Ghiringhelli, F. and Rébé, C. (2014). Liver X receptor beta activation induces pyroptosis of human and murine colon cancer cells. Cell Death Differ 21(12): 1914-1924.
  7. Végran, F., Berger, H., Boidot, R., Mignot, G., Bruchard, M., Dosset, M., Chalmin, F., Rébé, C., Dérangère, V., Ryffel, B., Kato, M., Prevost-Blondel, A., Ghiringhelli, F. and Apetoh, L. (2014). The transcription factor IRF1 dictates the IL-21-dependent anticancer functions of TH9 cells. Nat Immunol 15(8): 758-766.
  8. Végran, F. and Boidot, R. (2013). Survivin-3B promotes chemoresistance and immune escape by inhibiting caspase-8 and -6 in cancer cells. Oncoimmunology 2(11): e26328.
  9. Boidot, R., Végran, F. and Lizard-Nacol, S. (2014). Transcriptional regulation of the survivin gene. Mol Biol Rep 41(1): 233-240.
  10. Rébé, C., Végran, F., Berger, H. and Ghiringhelli, F. (2013). STAT3 activation: A key factor in tumor immunoescape. JAKSTAT 2(1): e23010.
  11. Végran, F., Mary, R., Gibeaud, A., Mirjolet, C., Collin, B., Oudot, A., Charon-Barra, C., Arnould, L., Lizard-Nacol, S. and Boidot, R. (2013). Survivin-3B potentiates immune escape in cancer but also inhibits the toxicity of cancer chemotherapy. Cancer Res 73(17): 5391-5401.
  12. Végran, F., Berger, H., Ghiringhelli, F. and Apetoh, L. (2013). Socs3 induction by PPARgamma restrains cancer-promoting inflammation. Cell Cycle 12(14): 2157-2158.
  13. Bugaut, H., Bruchard, M., Berger, H., Derangère, V., Odoul, L., Euvrard, R., Ladoire, S., Chalmin, F., Végran, F., Rébé, C., Apetoh, L., Ghiringhelli, F. and Mignot, G. (2013). Bleomycin exerts ambivalent antitumor immune effect by triggering both immunogenic cell death and proliferation of regulatory T cells. PLoS One 8(6): e65181.
  14. Berger, H., Végran, F., Chikh, M., Gilardi, F., Ladoire, S., Bugaut, H., Mignot, G., Chalmin, F., Bruchard, M., Derangère, V., Chevriaux, A., Rébé, C., Ryffel, B., Pot, C., Hichami, A., Desvergne, B., Ghiringhelli, F. and Apetoh, L. (2013). SOCS3 transactivation by PPARgamma prevents IL-17-driven cancer growth. Cancer Res 73(12): 3578-3590.
  15. Végran, F., Rebucci, M., Chevrier, S., Cadouot, M., Boidot, R. and Lizard-Nacol, S. (2013). Only missense mutations affecting the DNA binding domain of p53 influence outcomes in patients with breast carcinoma. PLoS One 8(1): e55103.
  16. Bruchard, M., Mignot, G., Derangère, V., Chalmin, F., Chevriaux, A., Végran, F., Boireau, W., Simon, B., Ryffel, B., Connat, J. L., Kanellopoulos, J., Martin, F., Rébé, C., Apetoh, L. and Ghiringhelli, F. (2013). Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth. Nat Med 19(1): 57-64.
  17. Hervieu, A., Rébé, C., Végran, F., Chalmin, F., Bruchard, M., Vabres, P., Apetoh, L., Ghiringhelli, F. and Mignot, G. (2013). Dacarbazine-mediated upregulation of NKG2D ligands on tumor cells activates NK and CD8 T cells and restrains melanoma growth. J Invest Dermatol 133(2): 499-508.
2 Protocols published
Liquid Luminescent DNA-precipitation Assay
Working on transcription factors requires studying interactions between protein and DNA. After identification of putative binding-sequences and motifs, Electrophoretic Mobility Shift Assay (EMSA) experiment is classically used to determine specific ...
Proximity Ligation Assay (PLA) Protocol Using Duolink® for T Cells
Protein-protein interaction experiments, such as co-immunoprecipitation (IP) assays, classically require tremendous amount of cells. This becomes a problem when your work focuses on rare cell populations (e.g., lymphocyte subtypes). O-link ...
We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.